

The background of the slide features a soft, out-of-focus image of several white chess pieces, including a king, a queen, and a knight, set against a light blue gradient. The pieces are positioned on the right side of the frame, with the king and queen in the upper right and a knight in the lower right. The overall aesthetic is clean and professional.

# GENERAL MEETING

Expansion of exclusive rights

April 2023

# DISCLAIMER

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Accordingly, neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.



# NEW OPPORTUNITIES

## TAPPING INTO US, CANADA AND HK



Expanding Invion's exclusive rights to USA, Canada and Hong Kong for Atherosclerosis and Infections Diseases (AID)



Invion to pay \$2.5M to RMW for expanded Infectious Diseases rights



Invion has option to pay a further \$1M (at its discretion) for Atherosclerosis rights for the three Territories



Any pre-clinical work or clinical trials are at Invion's election



RMW pays 75% (Invion 25%) of future non-clinical work and vice versa for clinical work



RMW will continue to fund all cancer R&D/clinical work in ANZ under existing R&D Services Agreement

# EXPANDING THE ADDRESSABLE MARKETS

## REACHING AN ADDITIONAL 377M PEOPLE



Indications	Existing Territories	New Territories
Atherosclerosis & Infectious Diseases (AID)	ANZ and Asia Pacific excluding Middle East, Russia and the specified territories of China, Hong Kong, Macau and Taiwan	USA, Canada and Hong Kong (IVX has the option to include atherosclerosis)
Cancers	ANZ and Asia Pacific excluding China (other than Hong Kong), Macau, Taiwan, Japan and South Korea	

# BROAD-SPECTRUM ANTI-MICROBIAL POTENTIAL

INFECTIOUS DISEASES: EFFECTIVE AGAINST VIRUSES, BACTERIA AND FUNGI *IN VITRO*

“Antimicrobial resistance (AMR) is one of the top 10 threats facing humanity”

*World Health Organisation<sup>1</sup>*

**Leading Institutions:** Viroclinics conducted virus tests & ACARE (University of Adelaide) conducted bacteria and fungi tests

**Broad Spectrum Potential:** *In vitro* tests showed Photosoft™ to be effective against several types of pathogens, including antibiotic-resistant superbugs

**Need for New Treatment Options:** Potential for Photosoft™ as a new treatment class for polymicrobial infections and/or where pathogens cannot develop drug resistance

“Given the general mode of action of PDT, we surmise that it is unlikely for superbugs to develop resistance to the compounds.”

*Prof Darren J. Trott, Director, Australian Centre for Antimicrobial Resistance Ecology (ACARE), University of Adelaide*

# EFFECTIVE AGAINST SARS-CoV-2 IN VITRO

## ANTIVIRAL ACTIVITY AGAINST DELTA AND OMICRON VARIANTS

Nine out of ten Photosoft™ compounds tested displayed antiviral activity against both Delta and Omicron variants of SARS-CoV-2

Multiple Photosoft™ compounds show effectiveness against SAR-CoV-2 at far lower concentrations than Remdesivir


Antiviral activity occurred once Photosoft™ compounds were activated with red light

Photosoft™ compounds tested demonstrated either no or low cytotoxicity

The global coronavirus treatment market is forecast to reach US\$49bn by 2027 (17.5% CAGR)\*


### SARS-CoV-2: Delta

Selected Photosoft™ Compounds vs. Remdesivir



### SARS-CoV-2: Omicron

Selected Photosoft™ Compounds vs. Remdesivir



▲ % Inhibition - Compound 7   
 ◆ % Inhibition - Remdesivir  
✱ % Inhibition - Compound 9   
 ■ % Inhibition - Compound 10


\*<https://www.coherentmarketinsights.com/market-insight/coronavirus-treatment-drugs-market-4312>

# EFFECTIVE AGAINST ZIKA AND DENGUE *IN VITRO*

## ANTIVIRAL ACTIVITY AGAINST ZIKA AND DENGUE


### Zika

Inhibition: Photosoft™ compound vs Monensin<sup>1</sup>



### Dengue

Inhibition: Selected Photosoft™ Compounds vs Monensin<sup>1</sup>



<sup>1</sup> Monensin is an antibiotic known to have activity against Zika in *in vitro* laboratory tests and was a control (benchmark) in these studies, but due to its *in vivo* toxicity cannot be used in humans

Several Photosoft™ compounds had >100x the activity of Monensin<sup>3</sup> (selected control) *in vitro*

One compound had an EC<sub>50</sub> (half max effective concentration) >90 times lower than Monensin

Zika virus is found in 86 countries and is linked to birth defects and other neurological complications

Dengue causes intense pain in joints and muscles, hence its nickname “breakbone fever”

Market is ~US\$17 billion in 2022<sup>1</sup> with no vaccines or treatments currently available<sup>2</sup>

Treatment market is forecast to hit US\$1.3 billion by 2030<sup>4</sup>

<sup>2</sup><https://www.marketdataforecast.com/market-reports/zika-virus-vaccines-market>

<sup>3</sup><https://www.who.int/news-room/fact-sheets/detail/zika-virus>


<sup>4</sup><https://www.biospace.com/article/-dengue-vaccines-market-size-to-reach-us-1-3-billion-by-2030/>

# EFFECTIVE AGAINST BACTERIA AND FUNGI

## MRSA SUPERBUG, E.COLI BACTERIA & CANDIDA ALBICANS FUNGUS

- Several Photosoft™ compounds showed activity *in vitro* against multiple strains of antibiotic-resistant MRSA bacteria, *Escherichia coli* bacteria and *Candida albicans* fungus\*
- MRSA is an antibiotic resistant bacteria that is difficult to treat, with the World Health Organisation (WHO) having declared antimicrobial resistance (AMR) as one of the top 10 threats facing humanity
- Photosoft™'s mode of action has the potential to make it unlikely for superbugs to develop resistance

\*Tests undertaken at the Australian Centre for Antimicrobial Resistance Ecology (ACARE), University of Adelaide




Note: The *in vitro* studies that were conducted at the University of Adelaide used enrofloxacin and amphotericin B as control antibiotics for the antibacterial and antifungal tests, respectively.

# WHAT IS ATHEROSCLEROSIS

## KEY CAUSE OF HEART DISEASE DEATHS GLOBALLY

- Atherosclerosis is a common condition where sticky substances called plaque builds up in arteries
- Preclinical studies underway to test if Photosoft™ can safely break down the plaque
- Diseases linked to atherosclerosis is the leading cause of death in the US\*
- About half of Americans between ages 45 and 84 have atherosclerosis and don't know it\*
- The global atherosclerosis market is estimated to grow to US\$58.2 bn by 2032+

### How Atherosclerosis can cause disability and death\*



\*National Heart, Lung, and Blood Institute (NIH) <https://www.nhlbi.nih.gov/health/atherosclerosis>  
+<https://www.futuremarketinsights.com/reports/atherosclerosis-market>

# THE WAY FORWARD

## MULTIPLE CATALYSTS AND MILESTONES

↑  
Cancer  
↓  
↑  
AID  
↓

### Australia

- **Proof of Concept (PoC)** Building on in vivo work further demonstrating both safety and efficacy profiles
- **Pre-clinical Preparations:** Building foundations for clinical trials in multiple indications and internationally
- **Clinical Trials:** With strong in vitro and in vivo results demonstrating both safety and efficacy profiles, and across multiple cancer types, the next steps will be to conduct clinical trials in multiple indications, including
  - Skin Cancer (superficial basal cell carcinoma)
  - Anogenital Cancer
  - Other solid tumour cancers TBC<sup>1</sup>
- **GMP manufacturing and scale up:** Building capacity to scale up for global late-stage trials and commercialisation

Global

**Expand Internationally:**  
Leveraging Australian clinical trial data into later stage programs in other major markets



<sup>1</sup> RMW Cho Group ("RMW") as licensor of Photosoft™ technology, is pursuing independent research in parallel with Invion's R&D efforts including a prostate cancer trial. The research is complementary/supplemental to Invion's development program. To the extent that Invion becomes aware of material information relating to RMW's studies, Invion will release the information to the ASX in compliance with its disclosure obligations (noting however that Invion is not involved in RMW's studies and does not have direct access to information)

# MANAGEMENT TEAM

## THE RIGHT EXPERTISE FOR SUCCESS



### **THIAN CHEW** **EXECUTIVE CHAIRMAN & CEO**

- Managing Partner, Polar Ventures
- Executive Director, Goldman Sachs
- Director, KPMG Consulting, Senior Manager KPMG
- Adj. Prof. HKUST, MBA/MA Wharton School



### **DR ANDREW STEPHENS** **HUDSON INSTITUTE, R&D**

- 15+ years in novel treatment R&D
- Founder, Ovarian Cancer Biomarker Group, Hudson Institute
- Postdoc. positions, the Uni. of Sydney and Prince Henry's Institute, PhD Biochemistry Monash Uni
- Published extensively, holds several patents



### **DR SEBASTIAN MARCUCCIO** **CHEMISTRY**

- 15+ years in Pharmaceutical and organic chemistry developmental research
- 16+ years commercial experience in molecular based companies (Managing Director / Founder)
- Adj. Prof. La Trobe University, PhD Organic Chemistry ANU



### **ALEXANDER BENNETT** **TECHNICAL ADVISOR, LIGHT**

- 35+ years in R&D, manufacturing and commercialisation of scientific instrumentation incl. ISO certifications
- GM Forensic Light Sources, Rofin Australia.
- Led Medical Light Source trial for PDT in skin cancers Peter MacCallum Cancer Centre



### **MELANIE LEYDIN** **CFO**

- 25+ years in accounting profession
- Partner, Vistra
- CFO and Co. Secretary multiple biotech companies
- Fellow Gov. Institute of Australia, Chartered Acc't



### **NICOLETTA MUNER** **REGULATORY AND CLINICAL DEVELOPMENT**

- 20+ years non-clinical and clinical drug development, quality, manufacturing, incl. EMA and US FDA approval
- Founder Canary Regulatory Affairs
- Global Regulatory Affairs, Clinuvel Pharmaceuticals
- Pre-clinical and regulatory affairs, Pfizer



### **LOUISE WHITE** **MANUFACTURING AND QUALITY**

- 35+ years in the pharmaceutical industry, 13 years in vaccine manufacturing, CSL, Partner SeerPharma
- Senior roles in virology R&D, bacterial vaccines production, quality control and production planning
- Registered auditor for APVMA



### **KIM STEEL** **CLINICAL TRIAL MANAGEMENT**

- 15+ years managing global and clinical drug and device studies from Phase I-IV across 14 countries
- Director, Sapro Consulting
- Project Director, Novotech
- Project Manager, Pacific Clinical Research Group



# Q&A SESSION

